The FT Latin America Healthcare and Life Sciences Summit, now in its second successful year, will provide a timely opportunity to examine and discuss the major trends shaping the public and private healthcare and life sciences industries of the region, as well as the emerging opportunities and challenges for investors.
It has been a year of both opportunity and challenge for the Latin America’s life science and healthcare industry. Currency depreciation and a slowing economy have constrained the ability of governments in the region to meet critical healthcare challenges. The Zika outbreak, meanwhile, has drawn attention to the enduring spectre of infectious diseases and the inadequacies of existing healthcare infrastructure, just as a growing epidemic of Non-Communicable Diseases (NCDs) threatens to overwhelm. Yet opportunities for investors in the region abound. Despite the current downturn, total healthcare expenditure is expected to grow significantly in the years ahead; international efforts will be needed to develop and finance vaccines, diagnostics and treatments for infection diseases; the scope for the private sector and for public–private partnerships can be expected to increase as cash-strapped governments try to fill critical infrastructure gaps, and products, service and solutions geared toward and the needs of region’s expanding elderly and chronically ill population –from new drugs, to home care and digital solutions- are a growing niche.